Search
for
Sort by
Research 241–270 of 931
- DRUG‐ASSOCIATED ALOPECIA
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Frequency of the Types of Alopecia at Twenty-Two Specialist Hair Clinics: A Multicenter Study
- Dermatologic Manifestations of Human Immunodeficiency Virus Infection
- Diagnosis and Management of Alopecia in Children
- The surgical treatment of cicatricial alopecia
- Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss
- Cicatricial (Scarring) Alopecias
- Primary cicatricial alopecia: Recent advances in understanding and management
- Acquired scalp alopecia. Part I: A review
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Study of<i>Demodex</i>mites: Challenges and Solutions
- Update on the dermatologic use of systemic glucocorticosteroids
- Pregnancy and the Skin
- Cetuximab-Associated Elongation of the Eyelashes
- Recent advances in the treatment of psoriasis
- Fatty acids and related lipid mediators in the regulation of cutaneous inflammation
- Scalp Itch: A Systematic Review
- Dermatologic manifestations of COVID‐19: a comprehensive systematic review
- Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge
- Skin disease in pregnancy
- Physiologic changes and dermatoses of pregnancy
- Cicatricial Alopecia Research Foundation meeting, May 2016: Progress towards the diagnosis, treatment and cure of primary cicatricial alopecias
- Skin signs of systemic diseases
- Hair and scalp disorders in women of African descent: an overview
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- The role of diet in the management of psoriasis: a scoping review
- What′s new in cicatricial alopecia?
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III